Omega Fund Management, LLC

CIK: 0001637359Latest portfolio: $286.5M · Q4 2025

Holdings

11

Total Value

$286.5M

New Positions

0

Closed Positions

1

Top Holdings

#StockSharesValue% PortfolioChangeType
1
NUVBNuvation Bio
8,081,089$72.4M25.27%-750,000
2
BBOTBridgeBio Oncology Therapeutics Inc.
3,289,661$41.2M14.37%
3
BBNXBeta Bionics Inc.
1,316,183$40.1M14.00%-603,942
4
BCAXBicara Therapeutics Inc.
2,204,650$37.1M12.95%
5
KMTSKestra Med Technologies Ltd
1,373,591$36.4M12.71%-272,302
6
UPBUpstream Bio Inc.
1,326,293$36.0M12.57%-30,000
7
ENGNenGene Holdings Inc.
876,357$7.9M2.76%+350K
8
ALMSAlumis Inc.
653,223$6.4M2.22%
9
SANASana Biotechnology, Inc.
843,750$3.4M1.20%
10
IMAImageneBio, Inc.
455,361$3.1M1.10%
11
REPLReplimune Group
248,672$2.4M0.84%

Quarterly Changes

New Positions

No new positions this quarter

Closed Positions

Increased Positions

NameSharesChange
ENGN876K+350K

Decreased Positions

NameSharesChange
NUVB8.1M-750000
BBNX1.3M-603942
KMTS1.4M-272302
UPB1.3M-30000

Sector Breakdown

Healthcare100.0% ($7.240641186401043e+40T)

Filing History

QuarterFiling DatePortfolio ValueHoldings
Q4 2025Feb 17, 2026$286.5M11
Q3 2025Nov 14, 2025$222.4B12
Q2 2025Aug 14, 2025$154.4B13
Q1 2025May 15, 2025$169.5B13
Q4 2024Feb 14, 2025$120.7B11

Fund Information

CIK0001637359
Most Recent FilingFeb 17, 2026
Number of Filings5

Omega Fund Management, LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $286.5M across 11 holdings. The largest position is Nuvation Bio (NUVB), representing 25.3% of the portfolio. Compared to the previous quarter, the fund opened 0 new positions and closed 1 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.